Management

Diede van den Ouden

CEO, Member of the Board of Directors (Management Board)

Diede van den Ouden has been a professional investor since 2008 with a proven track record as investor in listed company for many years. His knowledge and experience enable him to manage the constantly changing market conditions well. Since September 2024 Diede has served as CEO and President of Tonner Drones SA, listed on Euronext Growth Paris. From December 2022 to January 2025, he was CEO of Lavide Holding NV where he successfully led a reorganization and ensured a good future for this company by finding the right partner in Haerlem Capital. As an investor, he regularly played an advisory role to the management of other listed companies.

Aram Mangasarian

CSO

Aram Mangasarian was formerly CEO of TME Pharma where he restructured operations and focused its NOX-A12 program on the tumor microenvironment to target treatment of solid tumors and established an ophthalmology collaboration around NOX-E36. Aram brings twenty-five years’ experience in the biotechnology industry to TME Pharma.

Aram previously served as Vice-President Business Development for Novexel where he managed a worldwide patent portfolio and concluded a €150 million licensing agreement with Forest Laboratories (NYSE:FRX) for the beta-lactamase inhibitor now known as avibactam. He was also a key player in the acquisition of Novexel by AstraZeneca (NYSE:AZN) for up to $505 million. He began his career at ExonHit Therapeutics (now Eurobio Scientific, Euronext:ALERS), where he served in a Variety of roles eventually heading the business development function and led their $30 Million strategic alliance with Allergan (NYSE: AGN).
Aram holds a PhD in Biology from the University of California, San Diego, and has co-authored scientific articles in Immunity, Current Biology, The Journal of Immunotherapy of Cancer and the Journal of Virology amongst others. He also hods a BS from the University of Wisconsin, Madison in Biochemistry, Molecular Biology and English Literature and an MBA from INSEAD.

Jarl Ulf Jungnelius, MD, PhD

CMO

Jarl Ulf Jungnelius, MD, PhD joined the company as Chief Medical Officer in February 2017. He is an oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations.

Jarl Ulf was CEO of Isofol Medical AB. He also serves on boards of Biovica International, CarpoNovum, Oncopeptides and Ryvu Therapeutics. Jarl Ulf held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane^®, Gemzar^®, Alimta^® and Revlimid^®. He worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that post Jarl Ulf held leadership positions at Takeda, Pfizer, Eli Lilly & Company and VAXIMM, where he was responsible for clinical development of oncology programs as well as being involved in business development.

He received both a Bachelor of Science degree and his MD from the Karolinska Institute in Stockholm Sweden.